CuraCell Receives CTA Approval for Phase I/IIa Clinical Trial with Innovative TIL Therapy CC-38

Stockholm, Sweden – CuraCell Holding AB (CuraCell) today announced that the Paul-Ehrlich-Institut (PEI), the German federal authority for vaccines and biomedicines, has approved the company’s Clinical Trial Application (CTA) to initiate a Phase I/IIa clinical trial evaluating its novel autologous TIL (Tumor-Infiltrating Lymphocyte) therapy, CC-38, in patients with metastatic colorectal cancer and metastatic prostate cancer. The clinical trial is planned to commence in the second half of 2025.[CuraCell_Receives_CTA_Approval.jpg] TIL therapy harnesses the body’s own immune system by